We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Oramed Pharmaceuticals Inc | NASDAQ:ORMP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.03 | 1.19% | 2.56 | 2.55 | 2.59 | 2.6001 | 2.535 | 2.54 | 101,947 | 21:00:41 |
ORAMED PHARMACEUTICALS INC.
|
(Exact name of registrant as specified in its charter)
|
DELAWARE
|
001-35813
|
98-0376008
|
(State or Other Jurisdiction
|
(Commission
|
(IRS Employer
|
of Incorporation)
|
File Number)
|
Identification No.)
|
Hi-Tech Park 2/4 Givat Ram, PO Box 39098, Jerusalem, Israel
|
91390
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
5.1 |
Opinion of Zysman, Aharoni, Gayer and Sullivan & Worcester LLP.
|
10.1 |
At-the-Market Issuance Sales Agreement, dated April 2, 2015, by and between the Company and MLV & Co. LLC. (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2015.)
|
10.2 |
Amendment No. 1 to At-the-Market Issuance Sales Agreement, dated April 5, 2017, by and among the Company, MLV & Co. LLC and FBR Capital Markets & Co. (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2017.)
|
23.1 |
Consent of Zysman, Aharoni, Gayer and Sullivan & Worcester LLP (contained in Exhibit 5.1).
|
ORAMED PHARMACEUTICALS INC. | |||
|
By:
|
/s/ Nadav Kidron | |
Name: Nadav Kidron | |||
Title: President and CEO | |||
1 Year Oramed Pharmaceuticals Chart |
1 Month Oramed Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions